IBA Reports Full Year 2019 Results

Strong order intake and record backlog across all business lines

Significantly strengthened balance sheet

Louvain-La-Neuve, Belgium, 26 March 2020 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated annual results for the 2019 financial year.

	FY 2019** (EUR 000)		FY 2018* (EUR 000)		Variance (EUR 000)		Variance %
Proton Therapy and Other Accelerators	228 706		206 958		+21 748		+10.5%
Dosimetry	53 846		50 449		+ 3 397		6.7%
Total Net Sales	282 552		257 407		+25 145		9.8%
REBITDA	12 459		13 211		-752		-5.7%
% of Sales	4.4%		5.1%
REBIT	87		5 662		-5 575		-98.5%
% of Sales	0%		2.2%
Profit Before Tax	10 766	-894		11 660			N/A
% of Sales	3.8%	-0.3%
NET RESULT	7 610	-4 401		12 011			N/A
% of Sales	2.7%	-1.7%

* Dosimetry numbers (including RadioMed) re-integrated, following the decision in 2019 to retain the business